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ABSTRACT: The realization of a synthetic biology approach to microbial
(1R,2S,5R)-(−)-menthol (1) production relies on the identiﬁcation of a gene
encoding an isopulegone isomerase (IPGI), the only enzyme in the Mentha
piperita biosynthetic pathway as yet unidentiﬁed. We demonstrate that Δ5-3-
ketosteroid isomerase (KSI) from Pseudomonas putida can act as an IPGI,
producing (R)-(+)-pulegone ((R)-2) from (+)-cis-isopulegone (3). Using a
robotics-driven semirational design strategy, we identiﬁed a key KSI variant
encoding four active site mutations, which confer a 4.3-fold increase in activity
over the wild-type enzyme. This was assisted by the generation of crystal
structures of four KSI variants, combined with molecular modeling of 3 binding to
identify key active site residue targets. The KSI variant was demonstrated to
function eﬃciently within cascade biocatalytic reactions with downstream Mentha
enzymes pulegone reductase and (−)-menthone:(−)-menthol reductase to
generate 1 from 3. This study introduces the use of a recombinant IPGI,
engineered to function eﬃciently within a biosynthetic pathway for the production of 1 in microorganisms.
KEYWORDS: biosynthetic (−)-menthol production, ketosteroid isomerase, isopulegone isomerase, enzyme engineering, robotics
■ INTRODUCTION
Limonene and its related derivatives are the most abundant,
naturally sourced monoterpenoids known.1 These natural
products are commonly used in the perfume, fragrance, and
ﬂavor industries.2,3 For example, (R)-limonene ((R)-4) is the
major essential oil constituent of orange peels and is often
found in cleaning products.4 In contrast Mentha piperita
(peppermint) generates (S)-limonene ((S)-4), which is
subsequently converted into menthol isomers (Scheme
1A).2,5 The most commercially useful isomer is 1, known by
its characteristic cooling anesthetic eﬀects and aroma.6 It also
has antibacterial, anticancer, and anti-inﬂammatory activities,
making it a valuable natural product.7−10
Commercially, 1 is utilized both as a pure compound and as a
component of the essential oil of peppermint, with an estimated
30000 tons consumed annually.11 While the majority of 1 is
extracted from Mentha canadensis, a large proportion is
generated synthetically (US $300 million annually).12 The
two major synthetic routes to 1 are the Haarmann−Reimer
route from m-cresol and the Takasago synthesis utilizing β-
pinene.13 However, the ﬂavor and fragrance industries and/or
consumers may demand that these compounds be supplied
from natural sources, particularly when they are used as food
additives.
Naturally sourced peppermint oil can vary in both relative
composition of its monoterpenoid constituents and overall
yields due to ﬂuctuating environmental conditions. This leads
to price volatility and increased arable land competition for
more proﬁtable crops, such as biofuel biomass production.
Optimization of peppermint oil production through conven-
tional breeding methods is diﬃcult, as it is a sterile hybrid
plant.2,15 Additionally, puriﬁcation of 1 from essential oil
requires expensive and low-yielding steam-distillation and
ﬁltration processes to generate a usable product.16,17 Therefore,
alternative clean biosynthetic routes to these compounds are a
commercially attractive prospect to generate 1 with a “natural”
label.
One alternative “natural” route is to introduce the
biosynthetic pathway of 1 into cost-eﬀective and even food-
compatible microorganisms.18,19 This general synthetic biology
approach generates biological factories, where rapid ﬁne
chemicals production can be achieved sustainably using
nonpetroleum renewable feedstocks, with a reduced land
burden and higher product consistency and purity.20−22 Such
an approach has proved commercially successful in the
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semisynthetic industrial-scale production (ca. 35 tons per
annum) by Sanoﬁ of artemisinin, a major active ingredient in
modern malarial treatments. Similarly, the semisynthetic
production of Taxol has been demonstrated, where micro-
organism biofactories generated the precursor taxadiene using
introduced pathways.20
We recently described the incorporation of the M. piperita
based biosynthetic pathway from (R)-2 to 1 into Escherichia
coli.23 An in vitro protocol was established where 1 was
successfully generated, utilizing E. coli cell extracts as the
biocatalyst source. However, a more cost-eﬀective route would
be an in vivo approach, where the full pathways from simple
carbon sources to 1 would be incorporated and the
microorganisms would be grown on waste feedstock. The six
enzymatic steps from (S)-4 to 1 in Mentha sp. have been well
characterized,5,24−30 and the native enzymes for ﬁve of these
reactions have been sequenced and functionally expressed in E.
coli (Scheme 1A).4,5,23,28,30,31 The remaining enzyme is
isopulegone isomerase (IPGI), which catalyzes the double
bond migrating isomerization (C3−C4 to C2−C3) of 3 to (R)-
2 (Scheme 1B).26 Early studies with impure native Mentha
IPGI identiﬁed a 54 kDa protein complex2,24 exhibiting
cofactor-free isomerization, utilizing a mechanism similar to
bacterial Δ5-3-ketosteroid isomerases (KSI).26 Therefore, the
IPGI mechanism likely involves deprotonation of the C2α
hydrogen of 3 by an enzymatic proton acceptor (D40 in KSI),
to form an enolate intermediate (Scheme 1B), stabilized by
hydrogen-bonding residues (Y16 and D103 in KSI). A proton-
donating residue then transfers its proton to C4, leading to
double bond migration to C2−C3 and re-formation of the
carbonyl group. As no signiﬁcant ketosteroid isomerase-like
proteins have been annotated in plant genomes, the protein
sequence of native IPGI is likely to remain elusive until the
completion of the full annotation of the Mentha longifolia
genome sequence.32
To complete the construction of a pathway from (S)-4 to 1
in E. coli, we investigated a well-studied bacterial Δ5-3-
ketosteroid isomerase from Pseudomonas putida14,33,34 and
found that it exhibited low activity toward 3. To improve the
IPGI activity, we performed three rounds of automated
mutagenesis to improve yields of 2. The crystal structures of
four KSI variants were generated, to assist the structure-guided
mutagenesis approach to improve the binding of 3 to the
enzyme. Molecular dynamics simulations and DFT modeling
were applied to the most successful variant, to investigate the
mode of increase in activity. The performance of the optimized
KSI variant within both in vitro and in vivo biotransformation
cascades from 3 to 1 was demonstrated. Therefore, the
identiﬁcation and optimization of a substitute IPGI is a critical
step in the future generation of a potentially industrial E. coli
strain capable of producing “natural” 1.
■ EXPERIMENTAL SECTION
Design and Synthesis of KSI Variants. The wild-type
gene sequence encoding the Δ5-3-ketosteroid isomerase from
P. putida (UniProt ID: P07445) was designed using the
GeneGenie online tool, containing a C-terminal His6-tag.
35
Mutagenic oligonucleotides for the ﬁrst-generation libraries
encoding ambiguous codons for 16 residues were designed
optimized for E. coli expression using CodonGenie (Tables S1
and S2).36 Eight overlapping DNA oligonucleotides (up to 80
nt in length) were used to assemble the full length genes using
the SpeedyGenes gene synthesis method (section S2.5 in the
Supporting Information).37,38 Puriﬁed genes were ligated into
linearized pET21b (Novagen) to generate a C-terminally His6-
tagged enzyme by In-Fusion cloning (Clontech), according to
the manufacturer’s protocol. Cloning products were trans-
formed into T7 Express competent E. coli cells and grown on
LB agar plates containing 100 μg/mL ampicillin, followed by
incubation overnight at 37 °C.
Scheme 1. (A) Biosynthesis of 1 and (+)-Neoisomenthol (5) from (S)-4a and (B) Proposed KSI Catalytic Mechanism with 3, on
the Basis of the Known Mechanism of the Enzyme towards Δ5-3-Ketosteroids14
aAbbreviations: L3H = (−)-limonene-3-hydroxylase; IPDH = (−)-trans-isopiperitenol dehydrogenase; IPR = (−)-isopiperitenone reductase; IPGI =
(+)-cis-isopulegone isomerase; PGR = (+)-pulegone reductase; MMR = (−)-menthone:(−)-menthol reductase; MNMR = (−)-menthone:
(−)-neomenthol reductase.
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The second- and third-generation variants were constructed
using asymmetric PCR mutagenesis,39,40 followed by ligation
into linearized pET21b by In-Fusion cloning. These mutations
were designed as double or triple variants of the ﬁrst-generation
residues identiﬁed as providing hits (V88I, L99X, and D103S).
The ﬁnal variant was a combination of four individual positive
mutations (V88I/L99V/V101A/D103S).
Gene Synthesis of Mentha Biocatalysts. The protein
sequences for the following enzymes from M. piperita were
obtained from UniProt (http://www.uniprot.org): pulegone
reductase (MpPGR; Q6WAU0) and (−)-menthone:(−)-men-
thol reductase (MMR; Q5CAF4). The respective gene
sequences were designed and synthesized and subcloned into
pET21b by GeneArt (ThermoFisher), incorporating a C-
terminal His6-tag and applying codon optimization techniques
of rare codon removal for optimal expression in E. coli. Each
construct was transformed into E. coli T7 Express and grown on
LB agar plates containing 100 μg/mL ampicillin, followed by
incubation overnight at 37 °C.
Robotics-Driven Production and Puriﬁcation of
Variant Libraries. Robotic colony picking and auto induction
media inoculation (Formedium, 100 μg/mL ampicillin) of ﬁrst-
generation libraries were performed in deep-well plates
(Hamilton Robotics), including replica plating into LB
(Formedium, 100 μg/mL ampicillin) for glycerol stock
generation. Plates were covered with a Breathseal sealer
(Greiner Bio-One) and incubated at 30 °C and 1000 rpm for
24 h. Each variant underwent robotic cell lysis, extraction, and
puriﬁcation using Ni-NTA resin (Qiagen; 50 μL per variant)
prior to enzymatic assays (see section S3.1 in the Supporting
Information for details). Enzyme concentrations were deter-
mined using the Bradford assay (Bio-Rad) following the
manufacturer’s protocol.
KSI Variant Biotransformation Screen. Substrate 3 (85%
purity) was synthesized by Dr. Aisling Miller (University of
Manchester), using a combination of chemical and enzymatic
transformations.41 Reactions (200 μL) were performed in 50
mM Tris pH 7.0 containing 3 (1 mM) and KSI extract (189
μL) and incubated at 30 °C for 24 h (180 rpm). Samples were
prepared for GCMS analysis by solvent extraction with 180 μL
of ethyl acetate containing 0.01% sec-butylbenzene as the
internal standard and dried with anhydrous MgSO4. GC-MS
achiral quantitative analysis was conducted on a 7890B GC
coupled to a 5975 series MSD quadrupole mass spectrometer
and equipped with a 7693 autosampler (Agilent Technologies).
Chiral product analysis was performed by analyzing reactions
by GC using an Agilent Technologies 7890A GC system with
an FID detector and a Chirasil-DEX-CB column (Agilent; 25
m, 0.32 mm, 0.25 μm). Further chromatography details can be
found in section S3.2 in the Supporting Information.
Yields of (R)-2 were corrected for the initial concentration
present in substrate 3 (15%). Due to limitations in the quantity
of in-house synthesized 3, three colonies per plate were pooled
together to test for an increase in yield of (R)-2. Pooled
samples exhibiting an increased (R)-2 yield in comparison to
wild-type KSI were rescreened individually, as above, to identify
the well(s) responsible for the improved yield. Quantiﬁcation
was performed by comparing the peak areas to the calibration
curves of authentic standards. Vendor binary ﬁles were
converted to open mzXML data format42 using ProteoWizard
msConvert.43 Automated peak proﬁling and quantiﬁcation was
conducted using in-house scripts written in R.
Comparative Activity of the Variants. First-generation
KSI variant hits and later mutants generated by site-speciﬁc
mutagenesis were cultured from glycerol stocks in LB medium
containing 100 μg/mL ampicillin as above. The KSI-encoding
plasmids were extracted and puriﬁed (Macherey-Nagel) and
underwent Sanger sequencing to identify the mutation present.
Larger scale cultures (500 mL) were generated for each variant
in the same antibiotic-selective LB medium and incubated at 37
°C (180 rpm) to an OD600nm value of 0.6−0.8, followed by
induction with 0.1 mM isopropyl-β-D-thiogalactopyranoside
(IPTG). Cultures were incubated overnight at 25 °C (180
rpm) and the cells harvested by centrifugation (3000g for 5
min). Each variant underwent extraction (4 mL of lysis buﬀer)
and puriﬁcation (0.5 mL Ni-NTA resin) using the same
protocol and buﬀers as in the initial screen (section S3.1 in the
Supporting Information). Biotransformations were performed
with 1 mM 3 as above (10 μM KSI), and the variants that did
not display improved yield of (R)-2 above wild type (false
positives) were discarded.
Steady-State Reactions with (+)-cis-Isopulegone. Con-
tinuous steady-state reactions with 3 were performed with
selected puriﬁed variants to investigate the eﬀect of the
mutation(s) on the reaction rate. Reaction mixtures (100 μL)
were composed of 50 mM Tris pH 7.0 containing 1 mM 3
within UV-Star microplates (Greiner Bio-One) and covered
with a ClearVue sealing sheet. Product formation was detected
by monitoring the absorbance at 260 nm for 1 h at 20 °C using
a CLARIOstar microplate reader (BMG Labtech). Concen-
trations were determined by comparison to a standard curve
(Figure S1), and data were corrected for both 3 and (R)-2 loss
over 1 h (control substrate and product data).
Cascade Biocatalysis. The Mentha enzymes MpPGR and
MMR were produced (500 mL of culture; 20 °C) and puriﬁed
according to the method for the KSI variants (section S3.1 in
the Supporting Information). Reactions (200 μL) were
performed in 50 mM Tris pH 7.0 containing 10 μM KSI, 1
μM MpPGR, 0.3 μM MMR, 1 mM 3, and a cofactor recycling
system (10 U Sigma glucose dehydrogenase, 10 μM NADP+,
and 15 mM D-glucose) to supply MpPGR and MMR with
NADPH.23 Reaction mixtures were incubated at 30 °C for 24 h
(180 rpm), and the extracts were analyzed by GC-MS as before.
Pathway Assembly and in Vitro Activity. The genes
encoding KSI variant V88I/L99V/V101A/D103S, MpPGR,
and MMR and their respective ribosomal binding sequences
(RBS) were ampliﬁed by PCR and ligated into pET21b using
In-Fusion cloning to create an expression construct under the
control of one T7 promoter. The RBS of MMR was modiﬁed
by PCR mutagenesis to generate three constructs with lower
predicted translation initiation rates (Table S3). Each construct
was transformed into competent E. coli NEB5α cells and
underwent culture growth, plasmid puriﬁcation, and DNA
sequencing as before.
The plasmids were transformed into competent E. coli
NiCo21 (DE3) expression cells and cultured on LB agar
containing 100 μg/mL ampicillin. Single colonies were selected
and grown in 200 mL of phosphate buﬀered Terriﬁc Broth pH
7.0 containing 0.4% glycerol and 100 μg/mL ampicillin,
followed by induction with 0.1 mM IPTG. The cultures were
incubated overnight at 20 °C and harvested by centrifugation
(3000g). Soluble cell extracts were generated using lysis buﬀer
(3 mL pH 7.0), sonication, and centrifugation as above.
Cascade biocatalysis reactions were set up as before, except the
puriﬁed enzymes were replaced with 50 μL of cell extract.
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Protein Crystallization and Structure Solution. Puriﬁed
KSI variants D103S, V88I/L99V, V88I/L99V/D103S and
V88I/L99V/V101A/D103S (10 mg/mL) were crystallized
using a Mosquito robot (TTP Labtech) and the following
crystallization solutions: (i) 10−25% PEG3350 with 0.2 M
MgCl2, (ii) 10−25% PEG3350 with 0.2 M ammonium acetate
(pH 4.6), and (iii) 10−25% PEG3350 with 0.2 M ammonium
acetate (pH 5.5). Crystals were ﬂash-frozen in 30% glycerol and
data collected at the Diamond light source (beamlines IO4 and
IO3). Reﬂections were merged and scaled with Xia2.44 All
mutant structures were solved by molecular replacement using
Phaser-MR (CCP4)45 and wild-type KSI (PDB code: 1OPY) as
a search model. Initial model building was done with AutoBuild
(PHENIX)46 followed by iterative cycles of manual model
building and reﬁnement in COOT47 and Phenix.reﬁne,48
respectively. Mutations could be clearly identiﬁed in Fo − Fc
diﬀerence maps and were modeled accordingly. The ﬁnal data
collection and reﬁnement statistics are found in Table S4. The
atomic coordinates and structure factors (6F4Y, 6F50, 6F53,
and 6F54) have been deposited in the Protein Data Bank,
Research Collaboratory for Structural Bioinformatics, Rutgers
University, New Brunswick, NJ (http://www.rcsb.org/).
Molecular Modeling. DFT modeling was performed using
Gaussian09 revision D.01.49 An active site model was created
from the crystal structure of KSI with bound androstenedione
(6; PDB ID 1OHS) including the side chains and α-carbons of
the 15 ﬁrst-shell residues shown in Figure S4, with substrate 3
built in using the coordinates of the corresponding ligand 6
atoms as the starting point. Energy minimization was carried
out using the B3LYP hybrid functional and 6-31G(d) basis
sets50 with the D3 version of Grimme’s dispersion.51 Since the
active site is solvent exposed, a continuum solvent model was
used to mimic the shielding eﬀect of water. Molecular dynamics
simulations were carried out using Gromacs 4.6.1 with the
Gromos 53A6 force ﬁeld and periodic boundary conditions.52,53
For WT KSI, the crystal structure of KSI with bound 6 (PDB:
1OHS) was used, with substrate 3 built in using the coordinates
of the corresponding ligand 6 atoms as the starting point. For
KSI variant V88I/L99V/V101A/D103S, ligand 3 was placed in
the active site of the crystal structure (PDB: 1OPY) by aligning
the protein to the wild-type KSI model. The energy
minimization parameters are described in detail in section S6
in the Supporting Information.
■ RESULTS AND DISCUSSION
Identiﬁcation of KSI as a (+)-cis-Isopulegone Isomer-
ase. Prior studies with the partially puriﬁed native M. piperita
isomerase suggested its mechanism resembled that of the
bacterial Δ5-3-ketosteroid isomerase family (EC 5.3.3.1).26
These enzymes catalyze the isomerization of Δ5-3-ketosteroids,
such as 5(10)estrene-3,17-dione, to the equivalent Δ4-3-
ketosteroid by intramolecular transfer of the C4β proton to
the C6β position.54 Prior studies showed that KSI from P.
putida reacts with the truncated substrate 3-cyclohexen-1-one,
forming the more stable 2-cyclohexen-1-one.55 Therefore, we
postulated that KSI might react with the structurally related
compound 3 to generate (R)-2 using a similar mechanism
(Scheme 1B).
A C-terminally His6-tagged version of wild-type KSI from P.
putida was generated, and biotransformations with 3 showed
that 2 was formed (35% yield). Chiral GC analysis conﬁrmed
that the product generated was (R)-2, the enantiomeric form
required for 1 biosynthesis (Table S5).2 An additional minor
quantity (<1% yield) of the side product (−)-trans-isopulegone
(7) was also detected. As the (R)-2 yields were judged to be
too low for biotechnological applications, we employed a
directed evolution strategy to engineer KSI for improved
synthesis of (R)-2.
Automated Directed Evolution of KSI. Comparative
studies of KSI with single- and multiple-ring substrates showed
that, while the speciﬁcity (kcat/Km) is 27000-fold higher for
steroid substrates, the reaction rates were within 2-fold.55 This
suggests that remote binding interactions with steroid
substrates have a marked eﬀect on the strength of substrate
binding, and single-ring substrates such as 3 may have poor
binding aﬃnity. Therefore, our initial KSI mutagenesis strategy
was to increase binding of 3 by targeting every amino acid
known or predicted to interact with steroid substrates. An
examination of the cocrystal structure of wild-type KSI bound
to the reaction intermediate analogue equilenin (PDB 1OH0)34
showed that 16 residues were located within 5 Å of the ligand.
Given the overall apolar nature of the KSI active site and 3,
maintaining this environment would likely maximize our search
for optimized mutations while minimizing the size of the
variant libraries and subsequent screening eﬀort. Reducing the
number of screening assays was critical, given the limited
availability of the in-house-synthesized substrate 3.
Twelve of these residues were targeted for individual limited
randomizing mutagenesis, where the general physicochemical
properties of the amino acids were conserved (Table S1).
Residues Y16 and Y57 are both known to partake in H bonding
with the substrate carbonyl moiety; therefore, these residues
were mutated combinatorially, using an ambiguous codon
(WVC) that encodes other residues capable of H bonding.
Similarly, residues V88 and L99 were selected for combinatorial
mutations using an ambiguous codon (DTK) for hydrophobic
residues, given their close proximity to the substrate analogue.34
Variant sequences were created by gene synthesis using
ambiguous codons (Table S2) and constructed using the
SpeedyGenes protocols.37,38 In total, 158 variants were created
and screened for improvement in (R)-2 production using
automated robotic culturing and protein puriﬁcation protocols
(summarized in Figure S2). Comparative biotransformations
were performed with 3, with quantitation and product
identiﬁcation by GC-MS, to identify variants with activity
higher than that of wild-type KSI.
Four enzyme variants were identiﬁed as having minor
increases in (R)-2 yield (1.4−1.7 fold), three of which
contained mutations of residue L99 (L99I, L99V, and V88I/
L99V; Table 1). Interestingly, both L99I and L99V involve
mutations to a smaller side chain, suggesting that these changes
may aﬀect 3 binding by reducing steric hindrance. The fourth
improved variant D103S also contained a smaller side chain;
however, there was also a change from a negatively charged
moiety to a polar functionality. As a serine hydroxyl group can
participate in H bonding, this mutation might maintain the
native enzyme hydrogen-bonding interaction with the substrate
carbonyl group.
Second Round: Compiling Mutations. To investigate the
combinatorial eﬀect of the initial screen variants, the L99X-
containing single and double mutants were each combined with
D103S using asymmetric PCR mutagenesis.39,40 Each variant
was puriﬁed and underwent biotransformations to determine
any improvement in (R)-2 yield by GC-MS (Table 1).
Unfortunately, these double and triple variants showed only
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moderate improvements in (R)-2 yield in comparison to wild-
type enzyme (1.8−1.9-fold).
Third Round: Structure-Guided Mutation. To ensure
the mutations in the active site and surrounding residues did
not aﬀect the overall fold of KSI, we solved the X-ray crystal
structures of the four key variants D103S, V88I/L99V, V88I/
L99V/D103S, and V88I/L99V/V101A/D103S (Table S4).
Each of these structures showed backbone conformations
virtually identical with the cocrystal structure of wild-type KSI
bound to the reaction intermediate analogue equilenin (Figure
S3),34 with RMSD values of 0.427, 0.418, 0.443, and 0.357,
respectively. All of the mutations could be clearly identiﬁed in
Fo − Fc diﬀerence maps and were incorporated without any
major displacement of the backbone atoms or surrounding
residues. We did note minor rearrangements of backbone
atoms within the loop region 90−98 (results not shown). This
loop is exposed to the bulk solvent and shows above average B
factors in comparison to surrounding residues, implying the
observed diﬀerences are due to inherent ﬂexibility, rather than
any mutational changes to neighboring residues.
Inspecting the spatial arrangement of these mutations
showed that residue V101 was positioned directly between
L99V and D103S, highlighting it as another potential target for
mutagenesis (Figure 1B, inset). Given that most of the existing
variants resulted in a shortening of the amino acid side chain,
the triple variant was modiﬁed to incorporate the mutation
V101A. Biotransformations were performed on the KSI V88I/
L99V/V101A/D103S variant, which showed a more dramatic
increase in (R)-2 production over wild-type enzyme (4.5-fold;
Table 1). Therefore, the modiﬁcation of V101 to an alanine
residue has resulted in over a 2-fold increase in (R)-2 formation
over the triple variant.
To investigate the eﬀect of the mutations further, the speciﬁc
activity of the variants with substrate 3 was determined under
pseudo-steady-state conditions (1 h reactions). This method
takes advantage of the enolization of 3 to (R)-2, which results
in the development of a peak around 260 nm (Figure S1). First-
generation variants showed minor rate increases (around 1.3-
fold), while a near 2-fold improvement was seen with the triple
variant V88I/L99V/D103S (Figure 1B). The addition of
mutation V101A generated a 4.3-fold increase in speciﬁc
activity in comparison to the WT (61.17 μmol/(min mg) in
comparison to 14.16 μmol/(min mg); Figure 1B). Therefore,
the increases in the overall reaction rate mirror the increased
product yields detected in the 24 h biotransformations.
Modeling and Molecular Dynamics Simulations for
KSI Variants. We performed comparative DFT modeling and
MD simulations between wild-type KSI and variant V88I/
L99V/V101A/D103S to investigate the origin(s) of activity rate
changes. The DFT optimized model for wild type KSI suggests
that the substrate 3 carbonyl group hydrogen bonds with D103
(<2.0 Å), but the orientation is nonideal for catalysis due to a
less favorable interaction distance for the proton abstraction
step (Figure 2, Figure S4, and Scheme 1B). Additionally,
residue L99 has reoriented outward from the active site, causing
a twist in the β-hairpin from residue 88 to 99 (Figure S2).
MD simulations of variant KSI with 3 restrained in a reactive
conformation suggests that the decrease in bulk of variant
residues I88, V99, and A101 allows the substrate to comfortably
adopt this position (Figure 2B). The position of 3 looks more
ideal, with a D40−substrate hydrogen−oxygen distance of 2.04
Å in the DFT model. Therefore, the decrease in bulk of variant
residues I88, V99, and A101 has allowed this reorienting of the
substrate, while still maintaining a (slightly longer) hydrogen-
bonding interaction with residue S103 (D103 in wild type).
MD simulations with the variant model showed no
repositioning of the hairpin loop from 88 to 99 was necessary,
as 3 ﬁt more easily within the active site. Overall, molecular
simulations suggest that these four mutations have improved
Table 1. Biotransformations of Wild-Type and Variant KSI
with 3a
round variant activityb rel activity (fold)
wild type 13.88 ± 0.08 1.0
1 D103S 20.09 ± 1.16 1.4
L99I 23.58 ± 0.10 1.7
L99V 18.46 ± 0.48 1.3
V88I/L99V 19.39 ± 0.57 1.4
2 V88I/L99V/D103S 26.47 ± 1.59 1.9
L99V/D103S 25.51 ± 0.83 1.8
L99I/D103S 25.91 ± 0.58 1.9
3 V88I/L99V/V101A/D103S 63.10 ± 0.61 4.5
aDuplicate reactions (200 μL) were performed in 50 mM Tris pH 7.0
containing 1 mM 3 and 10 mM KSI. After a 24 h incubation at 30 °C
(180 rpm), reaction mixtures were extracted with 180 μL of ethyl
acetate containing 0.01% sec-butylbenzene and dried with anhydrous
MgSO4. Products were analyzed by GC-MS using a DB-WAX column.
bActivity is expressed as μM (R)-2 produced per μM KSI in 24 h.
Figure 1. Location of key active site mutations implicated in improving KSI activity toward 3. (A) Residues located in the equilenin-binding region
of wild type KSI from P. putida (PDB: 1OH0).34 The residues and equilenin are shown as atom colored sticks with yellow and green carbons,
respectively. Interactions are shown as red dotted lines. The backbone is shown as a gray cartoon. (B) Comparative steady-state activity of wild-type
and variant KSI enzymes. Reaction mixtures (100 μL) were composed of 50 mM Tris pH 7.0 containing 1 mM 3. The absorbance was monitored at
260 nm for 1 h at 20 °C. Inset: location of the variant residues in KSI V881/L99V/D103S. The backbone and mutations are shown as gray ribbons
and balls, respectively (blue balls for V101).
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binding of 3 in a functional conformation within the active site.
Therefore, the V88I/L99V/V101A/D103S variant was selected
for further studies to see if it can be used in cascade reactions
for the biosynthetic production of 1 from 3.
One-pot (−)-Menthol Production with Puriﬁed En-
zymes. Initial cascade reactions were performed with puriﬁed
enzymes to eliminate any interference from competing E. coli
enzymes present in whole cells and cell extracts (Table 2).
Interestingly, reactions with KSI variant V88I/L99V/V101A/
D103S showed the formation of ∼10% byproducts, such as
trans-isopulegone (7). This suggests that the presence of the
four mutations has altered the range of possible binding
conformations of 3, leading to additional isomer formation.
The pathway from 3 to 1 also requires the presence of two
Mentha enzymes, namely pulegone reductase (MpPGR)29 and
(−)-menthone:(−)-menthol reductase (MMR), to generate
(−)-menthone (8) and 1, respectively (Scheme 1A).2 Initial
biocatalytic reactions of puriﬁed MpPGR with (R)-2 showed it
produced near-equivalent yields of 8 and (+)-isomenthone (9)
(ratio 49:51; Table 2). This diﬀers slightly from previous
studies of a non-His6-tagged recombinant form of MpPGR,
which showed an 8:9 ratio of 55:45.29 However, this enzyme
showed a signiﬁcantly higher yield of 8 than had been seen with
the homologous enzyme from Nicotiana tabacum (NtDBR)
performed under the same reaction conditions.56 Similarly,
puriﬁed MMR-His6 demonstrated activity toward 8 similar to
that in previous studies,5 showing primarily 1 production
(Table 2).
Initial cascade biocatalytic reactions of puriﬁed KSI wild-type
and variant V88I/L99V/V101A/D103S with MpPGR and
MMR with 3 showed that the major product was an isomer of
isopulegol (results not shown). Chiral GC analysis of the
reaction mixture showed that the main isomer formed was
(+)-neoiso-isopulegol (10), with a minor proportion of
(−)-isopulegol generated (Figure S6).57 However, product 1
was also detected, with 5.1-fold higher yields obtained for
reactions containing V88I/L99V/V101A/D103S variant KSI
(46 μM vs 9 μM).
Subsequent reactions with each individually puriﬁed
biocatalyst showed that this side product was obtained by the
action of MMR on 3, which diﬀers from earlier studies.5
However, this apparent disparity is likely due to the 144-fold
reduction in the reaction time of the earlier study in
comparison to this work (6−9 min vs 24 h).5 It is likely that
Figure 2. Overlay of energy-minimized structure (green) and representative structure from MD simulations (brown) for (A) wild-type KSI and (B)
variant V88I/L99V/V101A/D103S modeled with 3 in the active site. The solvent-accessible surface areas for the substrate and residues 88, 99, and
101 from the representative and minimized structures, respectively, are shown as transparent surfaces. The dotted lines illustrate potential steric
clashes between the substrate and enzyme. The MD simulations were performed using Gaussian09 revision D.01.49
Table 2. Biotransformations of Individual Enzymes and Cascading Reactions with Mentha Monoterpenoidsa
substrate remaining/product yield (μM)
biocatalyst 3 (R)-2 8 9 3 5
Individual Enzymes
KSI WT 361.7 ± 11.5 210.4 ± 6.0 N/A N/A N/A N/A
KSI variantb,c 40.7 ± 0.7 436.3 ± 10.8 N/A N/A N/A N/A
MpPGR N/A 10.0 ± 1.1 153.3 ± 5.8 160.1 ± 4.5 N/A N/A
MMR N/A N/A 8.0 ± 2.0 N/A 280.7 ± 10.3 N/A
Cascading Reactions
cascadec 16.7 ± 1.2 10.3 ± 0.1 25.2 ± 0.9 16.6 ± 0.5 63.4 ± 3.8 11.1 ± 0.6
cell extractc 17.1 ± 0.1 11.5 ± 0.5 60.6 ± 1.9 34.8 ± 0.3 52.8 ± 0.9 18.6 ± 0.8
whole cellsc 32.5 ± 6.7 1.0 ± 2.1 44.7 ± 10.3 98.6 ± 2.4 158.8 ± 0.4 19.6 ± 0.1
aDuplicate reactions (200 μL) were performed in 50 mM Tris pH 7.0 containing 1 mM monoterpenoid substrate, enzyme(s), and cofactor recycling
system (10 U Sigma glucose dehydrogenase, 10 μM NADP+, and 15 mM D-glucose). After a 24 h incubation at 30 °C (180 rpm), reaction mixtures
were extracted with 180 μL of ethyl acetate containing 0.01% sec-butylbenzene and dried with anhydrous MgSO4. Products were analyzed by GC-MS
using a DB-WAX column (Figure S7). Reaction mixtures with individual enzymes had enzyme concentrations of 10 μM. The in vitro cascading
reaction had enzyme concentrations of 10, 2, and 0.3 μM for KSI variant, MpPGR, and MMR, respectively. Control biotransformations of each
compound in the absence of enzymes (data not shown) showed losses occurred over 24 h due to nonenzymatic degradation. Therefore, the product
yields are likely an underestimation of the true yields. The cell extract and whole cell slurry volumes in the cascading reactions were 50 μL. Substrates
are shown in boldface. N/A = not applicable. bKSI variant = V88I/L99V/V101A/D103S. cAdditional products were detected that were not
quantiﬁed (e.g., 7 and (+)-neoiso-isopulegol (10)).
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the mechanism of action of MMR with 3 proceeds in a manner
similar to that for the short chain dehydrogenase/reductase
(SDR) ketoreduction mechanism described previously for
MMR and MNMR with substrates 8 and 9 (Scheme 2).58
Unfortunately, the formation of 10 by MMR appeared to
dominate over the reaction with 8, likely due to the lack of the
latter substrate at the start of the reaction.
Subsequent cascade reactions were performed with a 30-fold
molar excess of KSI over MMR, to allow KSI activity with 3 to
predominate. Using this approach, we dramatically increased 1
titers (63.4 μM; 14.1% conversion; Table 2) relative to 10,
producing a near 1:1 ratio of products. In addition, a surprising
yet advantageous observation was that relatively lower levels of
9 (and subsequently 5) than expected were produced for
MMR, with a combined ratio of 76:24 ((8 + 1):(9 + 5)).
Therefore, these studies have demonstrated that KSI variant
V88I/L99V/V101A/D103S can be utilized in cascade reactions
as the ﬁrst step in generating 1 from 3.
Cascading Production of 3 Using Cell-Free Extracts
and Whole Cells. We have previously reported the biosyn-
thesis of menthol isomers from (R)-2, using E. coli cell extracts
expressing the enzymes NtDBR and MMR.23 To further extend
this approach, we developed a single expression construct in
pET21b containing KSI variant V88I/L99V/V101A/D103S,
MpPGR, and MMR, with each gene under the control of one
T7 promoter (Table S3). This enabled the IPTG-dependent
coexpression of all three genes in E. coli. Biotransformations
were performed using cell extracts with 3 in the presence of a
cofactor recycling system, the latter to supply MpPGR and
MMR with NADPH. As expected, the major product obtained
was 10, due to the promiscuous activity of MMR (results not
shown).
To mimic the eﬀect of increasing the KSI:MMR concen-
tration ratio in vivo, we modiﬁed the RBS sequence upstream of
MMR to three alternative ones, each with predicted translation
initiation rates (TIR) less than the existing rate of 4100 (1000,
500, and 200; Table S3).59,60 Of the three constructs, only that
containing an RBS with a predicted TIR of 500 showed any
MMR activity, leading to the production of both 1 and 10
(Table 2). Cell extracts of this construct yielded 53 μM of 1,
similar to that obtained with the puriﬁed enzyme one-pot
biocatalytic reactions. The higher levels of 8 and 9 detected
reﬂects the lower in vivo concentration of MMR within this
construct. Reactions were also conducted with whole cells,
producing nearly 3-fold higher levels of 1 in comparison to cell
extract biotransformations (159 μM, 27% total yield; Table 2)
with proportionally less 10.
These studies have demonstrated that these three enzymes
have great potential in an overall strategy for in vivo production
of 1 in E. coli. Ideally KSI V88I/L99V/V101A/D103S would be
incorporated into an E. coli construct containing all the
remaining enzymes required for 1 production from (S)-4
(Scheme 1A). This would enable one-pot biotransformations or
in vivo fermentations to be performed using the inexpensive
and renewable starting material (S)-4. Ultimately, the inclusion
of an (S)-4 production pathway would enable E. coli to produce
1 in vivo from simple sugars.61 This would avoid the addition of
high concentrations of toxic monoterpenoid precursors and
eliminate the need for exogenous cofactor recycling systems.
Additionally, the low in vivo concentration of 3 would likely
minimize pathway hijacking to form 10, increasing the overall
yields of 1.
■ CONCLUDING REMARKS
The implementation of a synthetic biology approach to
microbial 1 production has been hampered by the absence of
the sequence for the native Mentha pathway enzyme IPGI and
the lack of identiﬁcation of plant proteins exhibiting homology
to bacterial Δ5-3-ketosteroid isomerases known to catalyze this
reaction on steroid substrates. We took the approach of
engineering an existing bacterial Δ5-3-ketosteroid isomerase to
improve its activity toward 3, using a structure-modeling-
guided, semirational design to identify target residues. Our
implementation of a robotics platform to ensure rapid and
reproducible automated gene assembly, enzyme puriﬁcation,
and microscale biotransformation screening enabled the
identiﬁcation of potential variant biocatalysts with limited
substrate availability. The incorporation of four targeted
mutations into KSI enabled a 4.3-fold increase in IPGI activity,
generating a biotechnologically useful enzyme with signiﬁcant
in vivo activity. Further engineering studies could potentially
improve its functionality, thereby driving the cascade reactions
toward more eﬃcient 1 production.
This is the ﬁrst report of a non-Mentha enzyme with IPGI
activity, thereby identifying the “missing link” to complete the
enzymatic route from (S)-4 to 1. This will enable for the ﬁrst
time the full construction of a biosynthetic pathway for
microbial production of 1. The demonstration of successful 1
production from 3 by engineered E. coli adds to a growing
number of studies highlighting the potential usefulness of
microbial hosts in monoterpenoid production. It is anticipated
Scheme 2. Proposed Mechanism of Action of the NADPH-Dependent MMR-Catalyzed Reduction of 3 to 10a
aThis is adapted from the proposed SDR ketoreductase mechanism of MNMR with 8.58
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that integrating our existing KSI-MpPGR-MMR construct into
a larger chassis will enable the production of menthol isomers
from inexpensive precursors, providing a sustainable and
renewable production platform to meet the growing global
demand for natural menthol products.
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